Advances on the mechanism of caffeine in preventing bronchopulmonary dysplasia in preterms

Abstract

Caffeine citrate, as one type of methylxanthine, is often used to treat apnea in premature infants.Recent studies have found that it is not only used for extubation before weaning, shortening the time of mechanical ventilation, preventing apnea and reducing the occurance of intermittent hypoxic episodes, but also exerting lung protection by inhibiting inflammatory reactions, mitigating oxidative stress, improving pulmonary function and pulmonary angiogenesis.Thus, it could effectively reduce the risk of bronchopulmonary dysplasia in premature infants. Key words: Caffeine; Bronchopulmonary dysplasia; Preterm